|
EP3681540A1
|
|
Chlorotoxin agents and uses thereof
|
|
EP3446121A1
|
|
Prognosis of serous ovarian cancer using biomarkers
|
|
AU2015268693A1
|
|
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
AU2015252130A1
|
|
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
|
WO2016033190A1
|
|
Radiotracer compounds
|
|
AU2015201510A1
|
|
Chlorotoxin polypeptides and conjugates and uses thereof
|
|
AU2014202667A1
|
|
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
|
AU2013202884A1
|
|
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
AU2013201228A1
|
|
Antigenic gm-csf peptides and antibodies to gm-csf
|
|
AU2012254877A1
|
|
Anti-mesothelin antibodies
|
|
US2013116207A1
|
|
Compositions and methods for treating cancer
|
|
AU2012241059A1
|
|
High affinity antibodies that neutralize Staphylococcus enterotoxin B
|
|
AU2012205242A1
|
|
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
|
AU2012204129A1
|
|
CYP1B1 nucleic acids and methods of use
|
|
AU2011253933A1
|
|
Monoclonal antibodies that specifically bind to folate receptor alpha
|
|
EP3130605A1
|
|
Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
|
|
AU2011317088A1
|
|
Anti-folate receptor alpha antibody glycoforms
|
|
WO2011127235A1
|
|
Combination therapy for the treatment of dementia
|
|
US2011166112A1
|
|
Method for stimulating platelet production
|
|
CA2757745A1
|
|
Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
|
